natgillin/translations-raw huggingface dataset:
Tell your doctor if you have a drinking problem or consume alcohol (see section “Torisel contains ethanol [alcohol]”). 
Zdravniku povejte, če imate težave z alkoholom ali pijete alkohol (glejte poglavje “Zdravilo Torisel vsebuje etanol (alkohol)”).
In rats, these changes were accompanied by a decreased weight of accessory sex organs (epididymides, prostate, seminal vesicles). 
Pri podganah je te spremembe spremljala zmanjšana teža pomožnih spolnih organov (obmodkov, prostate, semenjakov).
General inflammatory responses, as indicated by increased fibrinogen and neutrophils, and/or changes in serum protein, were observed in mice, rats, and monkeys, although in some cases these clinical pathology changes were attributed to skin or intestinal inflammation as noted above. 
Splošne vnetne odzive, na katere kažejo zvišan fibrinogen in nevtrofilci in/ali spremembe serumskih beljakovin, so opazili pri miših, podganah in opicah, čeprav so v nekaterih primerih te kliničnopatološke spremembe pripisali vnetju kože ali črevesa, kot je opisano zgoraj.
A vaccination may be less effective or the use of certain vaccinations should be avoided during treatment with Torisel. 
Cepljenje bo morda manj učinkovito, nekaterih cepljenj pa se morate med zdravljenjem z zdravilom Torisel izogibati.
For intravenous use. 
za intravensko uporabo
Different end-filters can be used ranging in filter pore size from 0.2 microns up to 5 microns. 
Uporabljate lahko različne končne filtre, pri katerih sega velikost filtrirnih por od 0,2 mikrona do 5 mikronov.
if you have shortness of breath, cough, and/or fever. 
- če imate kratko sapo, kašljate in/ali imate vročino.
Torisel will always be prepared and given to you by a doctor or another healthcare professional as an intravenous infusion (into your vein). 
Zdravilo Torisel bo vedno pripravil in vam ga dal v obliki intravenske infuzije (v vašo veno) zdravnik ali drug zdravstveni delavec.
Hyperglycaemia/glucose intolerance/diabetes mellitus 
Hiperglikemija/intoleranca za glukozo/sladkorna bolezen
Abbreviations: CI = confidence interval; NA = not applicable. 
Okrajšave: IZ = interval zaupanja; NA = navedba smiselno ni potrebna.
Torisel is unlikely to influence the ability to drive and use machines. 
Ni verjetno, da bi zdravilo Torisel vplivalo na sposobnost vožnje in upravljanja strojev.
if the number of platelet (a type of blood cell that helps to clot blood) has decreased. 
- če je število krvnih ploščic (vrsta krvnih celic, ki sodeluje pri strjevanju krvi) zmanjšano.
Patients should be advised to report excessive thirst or any increase in the volume or frequency of urination. 
Bolnike je treba opozoriti, naj poročajo o prekomerni žeji ali zvečanju količine ali pogostnosti uriniranja.
In particular, you should inform your doctor or pharmacist if you are taking any of the following: 
Še posebej je pomembno, da zdravniku ali farmacevtu poveste, če jemljete kaj od naštetega:
Pharmacokinetic data on temsirolimus and sirolimus are available in patients up to age 79 years. 
No voljo so podatki o farmakokinetiki temsirolimusa in sirolimusa pri bolnikih, starih do 79 let.
Opportunistic infections such as PCP should be considered in the differential diagnosis. 
Pri diferencialni diagnozi je treba upoštevati tudi oportunistične okužbe, kot je PCP.
See section 4.4 for additional information concerning serious adverse reactions, including appropriate actions to be taken if specific reactions occur. 
Za dodatne informacije o resnih neželenih učinkih in ustrezne ukrepe v primeru pojava določenih neželenih učinkov glejte poglavje 4.4.
What Torisel is and what it is used for 
Kaj je zdravilo Torisel in za kaj ga uporabljamo
Patients should be advised that treatment with temsirolimus may be associated with an increase in blood glucose levels in diabetic and non-diabetic patients. 
Bolnike je treba opozoriti, da je zdravljenje s temsirolimusom lahko povezano z zvečano koncentracijo glukoze v krvi tako pri diabetikih kot nediabetikih.
Administration of corticosteroids may be considered; however, the efficacy of corticosteroid treatment in this setting has not been established. 
V poštev pride aplikacija kortikosteroidov, vendar učinkovitost zdravljenja s kortikosteroidi v teh okoliščinah ni bila dokazana.
Torisel must not be used during pregnancy, unless the risk for the embryo is justified by the expected benefit for the mother. 
Zdravila Torisel se ne sme uporabljati med nosečnostjo, če tveganja za zarodek ne upravičujejo pričakovane koristi za mater.
if your blood levels of cholesterol and triglycerides have increased. 
- če so ravni holesterola in trigliceridov v vaši krvi povečane.
The amount of alcohol in this medicinal product may impair the ability to drive or use machines (see section 4.7). 
Količina alkohola v tem zdravilu lahko zmanjša sposobnost vožnje in upravljanja strojev (glejte poglavje 4.7).
Tell your doctor if you experience new or worsening symptoms, or if you are taking or have recently taken medicines that weaken your immune system. 
Zdravniku povejte, če se vam pojavijo novi simptomi, če se že obstoječi simptomi poslabšajo ali če jemljete ali ste pred kratkim jemali zdravila, ki oslabijo imunski sistem.
The use of both an in-line and end-filter is not recommended (see sections 6.1 and 6.2). 
Uporaba obeh filtrov, zaporedno vključenega in končnega, ni priporočljiva (glejte poglavji 6.1 in 6.2).
Bleeding in the brain 
Krvavitve v možganih
Temsirolimus exhibits a polyexponential decline in whole blood concentrations, and distribution is attributable to preferential binding to FKBP-12 in blood cells. 
Temsirolimus kaže polieksponencialno zmanjševanje koncentracije v polni krvi, porazdelitev pa lahko pripišemo preferenčni vezavi na FKBP-12 v krvničkah.
The incidence and severity of adverse events is dose-dependent. 
Pogostnost in resnost neželenih učinkov sta odvisni od odmerka.
if you are receiving Torisel, you may be at increased risk of heart attack. 
- če prejemate zdravilo Torisel, ste lahko izpostavljeni povečanemu tveganju za srčni infarkt.
Patients receiving the starting dose of 175 mg weekly for the treatment of MCL must be followed closely to decide on dose reductions/delays. 
Bolnike, ki prejmejo začetni odmerek 175 mg na teden za zdravljenje MCL, je treba skrbno spremljati, da se lahko odločimo glede zmanjšanja/zakasnitve odmerka.
Sulfate or glucuronide conjugates were not detected in the human faecal samples, suggesting that sulfation and glucuronidation do not appear to be major pathways involved in the excretion of temsirolimus. 
V vzorcih človeškega blata niso odkrili sulfatnih ali glukuronidnih konjugatov, kar kaže na to, da sulfatacija in glukuronidacija nista pomembni poti, vpleteni v izločanje temsirolimusa.
Your doctor may delay the administration of Torisel until the wound is fully recovered as this medicine could interfere with the healing processes of pre-existing wounds. 
Zdravnik bo morda odložil zdravljenje z zdravilom Torisel, dokler se rana popolnoma ne zaceli, saj lahko to zdravilo vpliva na celjenje že obstoječih ran.
Hypersensitivity/infusion reactions 
Preobčutljivostne reakcije/reakcije na infuzijo
Investigator's choice therapies included: gemcitabine (intravenous: 22 [41.5%]), fludarabine (intravenous: 12 [22.6%] or oral: 2 [3.8%]), chlorambucil (oral: 3 [5.7%]), cladribine (intravenous: 3 [5.7%]), etoposide (intravenous: 3 [5.7%]), cyclophosphamide (oral: 2 [3.8%]), thalidomide (oral: 2 [3.8%]), vinblastine (intravenous: 2 [3.8%]), alemtuzumab (intravenous: 1 [1.9%]), and lenalidomide (oral: 1 [1.9%]). 
Zdravljenje, ki ga je izbral raziskovalec, je vključevalo: gemcitabin (intravensko: 22 [41,5 %]), fludarabin (intravensko: 12 [22,6 %] ali peroralno: 2 [3,8 %]), klorambucil (peroralno: 3 [5,7 %]), kladribin (intravensko: 3 [5,7 %]), etopozid (intravensko: 3 [5,7 %]), ciklofosfamid (peroralno: 2 [3,8 %]), talidomid (peroralno: 2 [3,8 %]), vinblastin (intravensko: 2 [3,8 %]), alemtuzumab (intravensko: 1 [1,9 %]) in lenalidomid (peroralno: 1 [1,9 %]).
It is harmful if you are suffering from alcoholism, and it is to be taken into account in pregnant or breast-feeding women, children and high-risk groups such as patients with liver disease or epilepsy. 
Škodljivo je, če trpite za alkoholizmom, vsebnost alkohola pa je treba upoštevati tudi pri nosečnicah ali doječih materah, otrocih in skupinah z velikim tveganjem, kot so bolniki z jetrnimi obolenji ali epilepsijo.
The use of temsirolimus has been associated with abnormal wound healing; therefore, caution should be exercised with the use of temsirolimus in the peri-surgical period. 
Uporaba temsirolimusa je bila povezana z nenormalnim celjenjem ran; zato je v perioperativnem obdobju pri uporabi temsirolimusa potrebna previdnost.
It is important that the recommendations in sections 4.2 and 6.6 be followed closely. 
Pomembno je, da natančno sledimo priporočilom v poglavjih 4.2 in 6.6.
If you experience any of these during the administration of Torisel, the doctor or nurse will stop the infusion. 
Če se vam med prejemanjem zdravila Torisel pojavi karkoli od naštetega, bo zdravnik ali medicinska sestra prekinil dajanje infuzije.
Grapefruit and grapefruit juice may increase blood concentrations of Torisel and should be avoided. 
Grenivke in sok grenivk lahko zvečajo koncentracijo zdravila Torisel v krvi in se jim je treba izogibati.
Although phospholipidosis has not been shown to be a risk for patients administered temsirolimus, it is possible that combined administration of temsirolimus with other amphiphilic agents such as amiodarone or statins could result in an increased risk of amphiphilic pulmonary toxicity. 
Čeprav niso dokazali, da bi bila fosfolipidoza možna nevarnost za bolnike, zdravljene s temsirolimusom, je možno, da bi kombinirana uporaba temsirolimusa z drugimi amfifilnimi sredstvi, na primer amiodaronom ali statini, lahko povzročila zvečano tveganje amfifilne toksičnosti za pljuča.
High concentrations resulted in complete cell growth inhibition in vitro, whereas inhibition mediated by FKBP-12/temsirolimus complex alone resulted in approximately 50% decrease in cell proliferation. 
Velike koncentracije so povzročile popolno zavrtje celične rasti in vitro, medtem ko je zavrtje, ki ga posreduje kompleks FKBP-12/temsirolimus, povzročilo približno 50-odstotno zmanjšanje proliferacije celic.
Because it is recommended that an H1 antihistamine be administered to patients before the start of the intravenous temsirolimus infusion, temsirolimus should be used with caution in patients with known hypersensitivity to the antihistamine or in patients who cannot receive the antihistamine for other medical reasons. 
Ker je priporočljivo bolnikom pred začetkom intravenske infuzije temsirolimusa dati antihistaminik H1, je treba pri bolnikih z znano preobčutljivostjo na antihistaminike ali pri bolnikih, ki iz drugih medicinskih razlogov ne smejo prejeti antihistaminika, temsirolimus uporabljati previdno.
Mean half-lives of temsirolimus and sirolimus were 17.7 hours and 73.3 hours, respectively. 
Povprečna razpolovna doba temsirolimusa je bila 17,7 ure, sirolimusa pa 73,3 ure.
Temsirolimus elimination by the kidneys is negligible; studies in patients with varying renal impairment have not been conducted (see sections 4.2 and 5.2). 
Izločanje temsirolimusa preko ledvic je zanemarljivo; študij pri bolnikih z različnimi ledvičnimi okvarami niso izvedli (glejte poglavji 4.2 in 5.2).
Some medicines can interfere with the breakdown or metabolism of Torisel and therefore dose adjustment of Torisel may be required. 
Nekatera zdravila lahko vplivajo na razgradnjo ali presnovo zdravila Torisel in zato bo morda potrebna prilagoditev odmerka zdravila Torisel.
Some patients were asymptomatic or had minimal symptoms with pneumonitis detected on computed tomography scan or chest radiograph. 
Nekateri bolniki so bili asimptomatski ali pa so imeli neznatne simptome in so jim pljučnico odkrili pri računalniški tomografiji ali rentgenskem slikanju prsnega koša.
Temsirolimus dose modifications based on weekly ANC and platelet counts ANC 
Spremembe odmerka temsirolimusa glede na tedensko ANC in trombocite ANC
Phospholipidosis has not been observed in mice or monkeys treated with temsirolimus, nor has it been documented in patients treated with temsirolimus. 
Fosfolipidoze niso opazili pri miših in opicah, ki so jim dajali temsirolimus, prav tako je niso dokumentirali pri bolnikih, zdravljenih s temsirolimusom.
if you have or have had eye problems like cataracts. 
- če imate ali ste kdaj imeli težave z očmi, kot so katarakte.
For subjects with neuroblastoma, the objective response rate was 5.3% (95% CI: 0.1%, 26.0%). 
Pri bolnikih z nevroblastomom je objektivni odziv na zdravljenje znašal 5,3 % (95 % IZ: 0,1 %; 26,0 %).
Due to the unknown risk related to potential exposure during early pregnancy, women of childbearing potential must be advised not to become pregnant while using Torisel. 
Zaradi neznanega tveganja, povezanega z možno izpostavljenostjo ploda v zgodnji nosečnosti, je treba ženskam v rodni dobi svetovati, naj med zdravljenjem z zdravilom Torisel ne zanosijo.
These symptoms might be caused by a sudden decrease of kidney function. 
Ti simptomi so morda posledica nenadnega poslabšanja delovanja ledvic.
IC50 values for inhibition of CYP2B6 and CYP2E1 by temsirolimus were 48 and 100 μM, respectively. 
Vrednosti IC50 za zaviranje CYP2B6 in CYP2E1 s temsirolimusom sta bili 48 oziroma 100 μM.
Other side effects with Torisel may include: 
Drugi neželeni učinki zdravila Torisel so lahko:
However, it is unlikely that whole blood concentrations of temsirolimus after intravenous administration of temsirolimus will inhibit the metabolic clearance of concomitant medicinal products that are substrates of CYP2C9, CYP2C8, CYP2B6 or CYP2E1. 
Vendar ni verjetno, da bi koncentracije temsirolimusa v polni krvi po intravenskem dajanju temsirolimusa zavirale presnovni očistek sočasnih zdravil, ki so substrati za CYP2C9, CYP2C8, CYP2B6 ali CYP2E1.
It is unknown whether temsirolimus is excreted in human breast milk. 
Ni znano, ali se temsirolimus izloča v materino mleko pri ljudeh.
The excretion of temsirolimus in milk has not been studied in animals. 
Izločanja temsirolimusa v mleko pri živalih niso proučevali.
You should also tell your doctor straight away: if you have cough, chest pain, difficulties in breathing. 
Prav tako brez odlašanja povejte zdravniku: - če kašljate, imate bolečine v prsih, težko dihate.
Others presented with symptoms such as dyspnoea, cough, and fever. 
Pri drugih so se pojavili simptomi, na primer dispneja, kašelj in vročina.
Temsirolimus is not recommended for use in paediatric patients (see sections 4.2, 4.8 and 5.1). 
Uporaba temsirolimusa pri pediatričnih bolnikih ni priporočljiva (glejte poglavja 4.2, 4.8 in 5.1).
Torisel may elevate triglycerides and/or cholesterol, and this may require treatment with lipid-lowering agents (medicines used to reduce cholesterol in the blood). 
Zdravilo Torisel lahko zviša trigliceride in/ali holesterol, zato bo morda potrebno zdravljenje s hipolipemiki (to so zdravila, ki znižujejo holesterol v krvi).
Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), clinical benefit rate, time to treatment failure (TTF), and quality adjusted survival measurement. 
Sekundarni opazovani dogodki so vključevali preživetje brez napredovanja bolezni (PFS - Progression-Free Surival), objektivni odziv na zdravljenje (ORR - Objective Response Rate), stopnjo klinične koristnosti, čas do prenehanja učinkovitosti zdravljenja (TTF - Time to Treatment Failure) in preživetja, popravljenega za kvaliteto življenja.
Torisel may cause non-specific interstitial pneumonitis. 
Zdravilo Torisel lahko povzroči nespecifično intersticijsko pljučnico.
The anti-tumour effect of temsirolimus, therefore, may also in part stem from its ability to depress levels of HIF and VEGF in the tumour or tumour microenvironment, thereby impairing vessel development. 
Zato lahko protitumorsko delovanje temsirolimusa deloma izvira tudi iz njegove sposobnosti za zniževanje ravni HIF in VEGF v tumorju ali mikrookolju tumorja, s čimer zavira razvoj žilja.
Inhibition of mTOR activity results in a G1 growth delay at nanomolar concentrations and growth arrest at micromolar concentrations in treated tumour cells resulting from selective disruption of translation of cell cycle regulatory proteins, such as D-type cyclins, c-myc, and ornithine decarboxylase. 
Zaviranje aktivnosti mTOR povzroči zakasnitev rasti G1 v nanomolarnih koncentracijah in zaustavitev rasti v mikromolarnih koncentracijah v zdravljenih tumorskih celicah, ki je posledica selektivne prekinitve translacije beljakovin, ki uravnavajo celični ciklus, kot so ciklini tipa D, c-myc in ornitinska dekarboksilaza.
The effect on the unbound concentrations of sirolimus has not been determined, but is expected to be larger than the effect on whole-blood concentrations due to the saturable binding to red blood cells. 
Učinka na nevezano koncentracijo sirolimusa niso ugotavljali, zaradi nasičene vezave na rdeče krvničke pa je pričakovati, da bo večji kot učinek na koncentracijo v polni krvi.
The safety and efficacy of intravenous temsirolimus for the treatment of relapsed and/or refractory MCL were studied in the following Phase 3 clinical study. 
Varnost in učinkovitost intravenskega temsirolimusa za zdravljenje recidivnega in/ali proti zdravljenju odpornega MCL so proučevali v naslednji klinični študiji 3. faze.
What Torisel looks like and contents of the pack 
Izgled zdravila Torisel in vsebina pakiranja
There have been cases of non-specific interstitial pneumonitis, including fatal reports, occurring in patients who received weekly intravenous temsirolimus. 
Opisani so bili primeri nespecifične intersticijske pljučnice, tudi smrti, pri bolnikih, ki so vsak teden intravensko dobivali temsirolimus.
6 hours when stored below 25°C and protected from light. 
6 ur, če je shranjeno pri temperaturi do 25 C in zaščiteno pred svetlobo
When mTOR activity is inhibited, its ability to phosphorylate, and thereby control the activity of protein translation factors (4E-BP1 and S6K, both downstream of mTOR in the P13 kinase/AKT pathway) that control cell division, is blocked. 
Ko je aktivnost mTOR zavrta, je blokirana njegova sposobnost fosforilacije in s tem nadzorovanja aktivnosti faktorjev translacije beljakovin (4E-BP1 in S6K, obe v fazah, ki sledita mTOR v presnovni poti P13 kinaza/AKT), ki nadzirajo celično delitev.
Dose reduction level 
Ravni zmanjšanja odmerka
If the patient cannot maintain ANC 1.0 x 109/l and platelets 50 x 109/l on the new dose reduction level, then the next lower dose should be given once the counts have recovered. 
Če bolniku ne moremo vzdrževati ANC  1,0 x 9/l in trombocitov  50 x 10 9/l na novi ravni zmanjšanja odmerka, je treba dati naslednji zmanjšani odmerek, potem ko se ANC in koncentracija trombocitov popravita.
P-value 
Vrednost p
After 12 weeks of treatment, no response was observed in subjects with rhabdomyosarcoma or high-grade glioma. 
Po 12 tednih zdravljenja niso opazili nobenega odziva pri bolnikih z rabdomiosarkomom ali gliomom visoke stopnje.
However, sirolimus, the main metabolite of temsirolimus, is excreted in milk of lactating rats. 
Se pa sirolimus, ki je glavni presnovek temsirolimusa, izloča v mleko doječih podgan.
Do not use this medicine after the expiry date, which is stated on the vial label and carton. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki na viali in kartonski škatli poleg oznake ''Uporabno do'' oziroma ''EXP''.
Concomitant use of angiotensin-converting enzyme (ACE) inhibitors and/or calcium channel blockers 
Sočasna uporaba zaviralcev angiotenzinske konvertaze (ACE) in/ali zaviralcev kalcijevih kanalčkov
Studies in animals have shown reproductive toxicity. 
Študije na živalih so pokazale vpliv na sposobnost razmnoževanja.
There is no relevant use of temsirolimus in the paediatric population for the indications of RCC and MCL. 
Pediatrična populacija Temsirolimus ni namenjen za uporabo pri pediatrični populaciji za indikaciji RCC in MCL.
Starting dose 175 mg 
Začetni odmerek 175 mg
No specific dose adjustment is necessary in elderly patients. 
Starostniki Pri starejših bolnikih posebno prilagajanje odmerka ni potrebno.
Use of temsirolimus in patients with MCL with moderate or severe hepatic impairment. 
Uporaba temsirolimusa pri bolnikih z MCL z zmerno ali hudo okvaro jeter.
Torisel is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors (see section 5.1). 
Zdravilo Torisel je indicirano kot zdravilo prvega izbora za zdravljenje odraslih bolnikov z napredovalim karcinomom ledvičnih celic (RCC - Renal Cell Carcinoma), ki imajo vsaj tri od šestih prognostičnih dejavnikov tveganja (glejte poglavje 5.1).
Bleeding into the brain in patients with brain tumours or who are on blood thinners, eye bleeding. 
Krvavitev v možgane pri bolnikih z možganskimi tumorji ali pri tistih, ki se zdravijo s sredstvi za preprečevanje strjevanja krvi, krvavitve v očeh.
An in-line polyethersulfone filter with a pore size of not greater than 5 microns is recommended for administration to avoid the possibility of particles bigger than 5 microns being infused. 
Za dajanje zdravila priporočajo polietersulfonski filter v infuzijskem sistemu s porami, ki niso večje od 5 mikronov, da se izognete možnosti, da bi infundirali delce, večje od 5 mikronov.
In the 25 mg arm (n = 36), all patients had metastatic disease; 4 (11%) had no prior chemo- or immunotherapy; 17 (47%) had one prior treatment, and 15 (42%) had 2 or more prior treatments for RCC. Twenty-seven (27, 75%) had undergone a nephrectomy. 
V kraku s 25 mg (n = 36) so imeli vsi bolniki metastatsko bolezen; 4 (11 %) kemoterapije ali imunoterapije prej niso imeli; 17 (47 %) jih je imelo po eno predhodno zdravljenje, 15 (42 %) pa po 2 ali več predhodnih zdravljenj zaradi RCC. Sedemindvajset (27, 75 %) jih je imelo nefrektomijo.
a Based on log-rank test stratified by prior nephrectomy and region. 
Na podlagi testa log-rank, stratificiranega po predhodni nefrektomiji in regiji.
Hypersensitivity to temsirolimus, its metabolites (including sirolimus), polysorbate 80, or to any of the excipients listed in section 6.1. 
Preobčutljivost na temsirolimus, njegove presnovke (med drugim sirolimus), polisorbat 80 ali katerokoli pomožno snov, navedeno v poglavju 6.1.
Manufacturer Wyeth Lederle S.r.l. 
Izdelovalec Wyeth Lederle S.r.l.
Temsirolimus distribution is dose-dependent with mean (10th, 90th percentiles) maximal specific binding in blood cells of 1.4 mg (0.47 to 2.5 mg). 
Porazdelitev temsirolimusa je odvisna od odmerka s povprečno (10., 90. percentila) maksimalno specifično vezavo v krvničkah 1,4 mg (od 0,47 do 2,5 mg).
In population pharmacokinetic-based data analysis, increased body weight (between 38.6 and 158.9 kg) was associated with a two-fold range of trough concentration of sirolimus in whole blood. 
Na podlagi analize podatkov s populacijsko farmakokinetiko je bila zvečana telesna masa (med 38,6 in 158,9 kg) povezana z dvakrat večjim razponom najmanjših koncentracij sirolimusa v polni krvi.
At the discretion of the physician, treatment may be resumed after the administration of an H1-receptor antagonist (diphenhydramine or similar antihistamine) and a H2-receptor antagonist (intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the temsirolimus infusion. 
Po zdravnikovi presoji se lahko zdravljenje nadaljuje potem, ko bolnik prejme antagonist receptorjev H1 (difenhidramin ali podoben antihistaminik) in antagonist receptorjev H2 (famotidin 20 mg intravensko ali ranitidin 50 mg intravensko) približno 30 minut pred ponovnim začetkom infuzije temsirolimusa.
Torisel can decrease the number of blood cells that help in clotting and resisting infection. 
- zdravilo Torisel lahko zmanjša število krvnih celic, ki sodelujejo pri strjevanju krvi ter premagovanju okužb.